On January 19, 2024 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that it will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Feb. 1 (Press release, Merck & Co, JAN 19, 2024, View Source [SID1234639365]). During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com.

All participants may join the call by dialing (800) 779-6561 (U.S. and Canada Toll-Free) or (773) 756-4619 and using the access code 5958465.